Medical device manufacturer Medtronic reported third-quarter earnings that exceeded analyst projections Tuesday, powered by increased sales of cardiac equipment and continuous glucose monitors.
The strong performance reflects a broader trend affecting medical technology companies, as healthcare facilities see growing demand for medical procedures. Insurance companies are reporting higher medical loss ratios, suggesting patients are scheduling more treatments and procedures than in recent periods.
The company kept its financial outlook unchanged for fiscal year 2026, projecting adjusted earnings per share between $5.62 and $5.66.
Key growth areas for Medtronic include its advanced pulsed field ablation technology and transcatheter aortic valve replacement systems, both representing less invasive treatment options that physicians are increasingly adopting.
The cardiovascular division, representing approximately 40% of total company sales, posted revenue growth of 13.8% reaching $3.46 billion for the quarter. Much of this increase came from strong performance in the pulsed field ablation product line.
This innovative technology delivers targeted high-energy electrical pulses to eliminate specific heart tissue areas, helping to minimize irregular heartbeat episodes in patients.
In the diabetes monitoring space, Medtronic faces competition from Abbott and Dexcom as the continuous glucose monitoring market grows. Patients are increasingly choosing these convenient devices that eliminate the need for traditional finger-stick blood testing.
Total quarterly revenue reached $9.02 billion, surpassing Wall Street predictions of $8.91 billion based on LSEG data.
The company posted adjusted quarterly earnings of $1.36 per share, topping the average analyst forecast of $1.33 per share.
Healthcare giant Johnson & Johnson, a larger competitor, also reported positive results with medical technology sales rising 7.5% year-over-year during the same period, particularly benefiting from strong electrophysiology and cardiac device sales.
